Cancer jab can eradicate tumours in patients, trial shows
4 hours ago
- #Cancer Treatment
- #Medical Trial
- #Immunotherapy
- Triple-action cancer jab (amivantamab) showed unprecedented efficacy in eradicating entire tumors in patients with advanced, treatment-resistant cancers.
- International trial involved 102 patients with head and neck cancer (non-HPV type), a typically hard-to-treat form; tumors shrank or disappeared in 43 patients, with 15 experiencing complete eradication.
- The jab works by blocking EGFR and MET pathways to inhibit tumor growth and escape, while activating the immune system to attack tumors.
- Amivantamab is administered as a subcutaneous injection, making treatment quicker and more convenient than intravenous methods, with mild to moderate side effects.
- Positive results were also seen in lung cancer patients, and the drug is now being evaluated in about 60 clinical trials for various cancers.
- Patient testimonials highlight significant improvements in quality of life, including reduced pain, normal diet restoration, and normal speech after treatment.
- Median survival for patients receiving amivantamab was 12.5 months, representing a meaningful advance for those with limited treatment options.